Open Access4CPS-150 Use of adalimumab for hidradenitis suppurativa
Author(s) -
MD Gil-Sierra,
JC Garciadeparedes-Esteban,
E Ríos-Sánchez,
MDP Briceño-Casado,
C Palomo-Palomo,
J Diaz-Navarro,
EJ Alegre-Del Rey,
C Martinez-Diaz,
JF López-Vallejo,
JM Borrero-Rubio
Publication year - 2018
Publication title -
section 4: clinical pharmacy services
Language(s) - English
Resource type - Conference proceedings
DOI - 10.1136/ejhpharm-2018-eahpconf.241
Subject(s) - adalimumab , medicine , hidradenitis suppurativa , regimen , infliximab , adverse effect , clinical endpoint , surgery , gastroenterology , tumor necrosis factor alpha , clinical trial , disease
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom